The Therapeutic Goods Administration (TGA) has announced new safety regulations for Vitamin B6 supplements, tightening access to high-dose products after updating Australia’s Poisons Standard.
The decision follows growing concerns about the risk of peripheral nerve damage linked to long-term use of high-dose Vitamin B6. The TGA’s review—which included a public consultation phase—found strong support for stricter controls to protect consumers.
Under the new rules, oral Vitamin B6 products containing more than 50mg but less than 200mg will no longer be available for self-selection. From 1 June 2027, these supplements will be supplied behind the counter at pharmacies, with pharmacists required to ask questions about intended use and provide safety advice.
Products containing over 200mg of Vitamin B6 will continue to require a doctor’s prescription.
The delayed implementation date gives pharmacies, manufacturers, and healthcare providers time to update product labels and adjust stock arrangements.
The TGA says the updated controls “strike a balance” between the benefits of low-dose Vitamin B6 and the known risks of high-dose, long-term ingestion. Excessive Vitamin B6 may lead to sensory neuropathy, a form of nerve damage that affects feeling in the hands and feet.
Most adults only require 1.1–1.7mg of Vitamin B6 per day, making high-strength products far above standard dietary needs. Deficiency is uncommon but can occur in older adults and people with alcohol dependence, obesity, or certain kidney, liver, or autoimmune conditions.
Consumers are encouraged to review labels on multivitamins and regular medications, as Vitamin B6 may appear under names such as pyridoxine, pyridoxamine, or pyridoxal.
Anyone concerned about their Vitamin B6 intake should speak with a doctor or pharmacist. Side effects or suspected adverse reactions can be reported directly to the TGA via the Adverse Event Reporting System.
Report an adverse event HERE.
Proudly Australian owned and operated